-15%PE-22-28 Spray
Spadin analogue · 10mL nasal spray · Limitless Life Nootropics
Price with PeptideDeck coupon applied at checkout
PeptideDeck
≥98% Purity
Third-party verified
10mL Spray
Nasal delivery
GMP Compliant
USA manufactured
Heptapeptide
TREK-1 blocker
About PE-22-28
PE-22-28 is a heptapeptide analogue of spadin that acts as a potent TREK-1 potassium channel blocker. TREK-1 has been identified as a target for rapid-acting antidepressant effects, and PE-22-28 represents a refined approach to modulating this channel for mood and cognitive support. The nasal spray form enables direct CNS delivery for efficient neuropeptide action.
Product Specifications
Key Benefits
Antidepressant-Like Effects
PE-22-28 blocks TREK-1 potassium channels, a validated target for rapid-acting antidepressant effects, producing mood-elevating responses in preclinical models.
Cognitive Enhancement
By modulating potassium channel activity and enhancing serotonergic signaling, PE-22-28 supports improved cognitive function, learning, and mental flexibility.
Neuroplasticity Support
PE-22-28 promotes neuroplasticity through BDNF pathway activation and enhanced synaptic signaling, supporting the brain's ability to form new neural connections.
Rapid-Acting Mood Modulation
Unlike traditional antidepressants that require weeks to take effect, TREK-1 blockade by PE-22-28 produces rapid mood-modulating effects in research models.
BDNF Pathway Activation
PE-22-28 activates Brain-Derived Neurotrophic Factor signaling cascades, supporting neuronal survival, synaptic strength, and long-term potentiation.
Frequently Asked Questions
What is PE-22-28?
PE-22-28 is a heptapeptide (7 amino acids) analogue of spadin that acts as a potent blocker of the TREK-1 potassium channel. It was developed as a refined, more stable version of spadin with enhanced selectivity for the TREK-1 target, which has been identified as a promising target for rapid-acting antidepressant effects.
How does TREK-1 blocking work?
TREK-1 (TWIK-Related Potassium Channel 1) is a two-pore domain potassium channel expressed in brain regions associated with mood regulation. When TREK-1 is active, it hyperpolarizes neurons and reduces excitability. Blocking TREK-1 increases neuronal excitability and enhances serotonergic neurotransmission, producing antidepressant-like effects.
How does PE-22-28 compare to traditional antidepressants?
Traditional antidepressants (SSRIs, SNRIs) typically require 2-6 weeks to produce therapeutic effects by gradually modulating monoamine levels. PE-22-28 targets TREK-1 channels directly, producing rapid-onset effects in preclinical models — similar to the rapid-acting profile seen with ketamine but through a distinct mechanism.
How should PE-22-28 spray be stored?
Store PE-22-28 nasal spray in a cool, dry place away from direct sunlight. Refrigeration (2-8°C) is recommended for optimal peptide stability. Keep the bottle tightly sealed between uses.
What is Spadin?
Spadin is a 17-amino acid peptide naturally released from the maturation of the sortilin receptor (NTSR3). It was the first identified natural blocker of TREK-1 channels and demonstrated antidepressant-like properties. PE-22-28 is a shorter, optimized analogue of spadin with improved stability and potency at the TREK-1 target.
How PE-22-28 Works
PE-22-28 blocks TREK-1 (TWIK-Related Potassium Channel 1), a two-pore domain potassium channel that has been genetically linked to depression. When TREK-1 is active, it reduces neuronal excitability by allowing potassium efflux. Blocking this channel increases neuronal firing rates in mood-regulating brain regions.
Inhibition of TREK-1 by PE-22-28 produces rapid antidepressant-like effects similar to its parent compound spadin, but with enhanced stability and potency. This mechanism enhances serotonergic neurotransmission and activates BDNF signaling cascades.
The resulting increase in BDNF expression supports neuroplasticity, synaptic strengthening, and long-term potentiation — molecular processes that underlie both mood regulation and cognitive function, explaining PE-22-28's dual nootropic and mood-modulating profile.